<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE ichicsr>
<ichicsr lang="en">
<ichicsrmessageheader>
<messagetype>ichicsr</messagetype>
<messageformatversion>2.1</messageformatversion>
<messageformatrelease>1.0</messageformatrelease>
<messagenumb>c7c9d7d3-9ffe-11ee-8bed-28dfeb6bed73-BIO</messagenumb>
<messagesenderidentifier>simplesafety</messagesenderidentifier>
<messagereceiveridentifier>ss</messagereceiveridentifier>
<messagedateformat>204</messagedateformat>
<messagedate>20230627181511</messagedate>
</ichicsrmessageheader>
<safetyreport>
<safetyreportversion>0</safetyreportversion>



<transmissiondateformat>102</transmissiondateformat>
<transmissiondate>20230627</transmissiondate>
<reporttype>1</reporttype>
<serious>2</serious>










<authoritynumb>3405041927228202300005</authoritynumb>




<sender>

<senderorganization>simplesafety</senderorganization>
</sender>
<receiver>

<receiverorganization>ss</receiverorganization>
</receiver>
<patient>
<patientinitial>unknown</patientinitial>




<patientbirthdateformat>102</patientbirthdateformat>
<patientbirthdate>20050611</patientbirthdate>
<patientonsetage>18</patientonsetage>
<patientonsetageunit>801</patientonsetageunit>


<patientagegroup>4</patientagegroup>
<patientweight>nan</patientweight>

<patientsex>1</patientsex>




<patientdeath>
<patientdeathdateformat>102</patientdeathdateformat>


</patientdeath><patientdeathcause>

<patientdeathreport>0</patientdeathreport>
</patientdeathcause><medicalhistoryepisode>

<patientepisodename>10001936</patientepisodename>






</medicalhistoryepisode><reaction>
<primarysourcereaction>Eye stinging</primarysourcereaction>





<reactionstartdateformat>102</reactionstartdateformat>
<reactionstartdate>20230611</reactionstartdate>






<reactionoutcome>1</reactionoutcome>
</reaction><drug>
<drugcharacterization>1</drugcharacterization>
<medicinalproduct>Levofloxacin Hydrochloride Eye Drops</medicinalproduct>






<drugstructuredosageunit>031</drugstructuredosageunit>






<drugdosageform>Ophthalmic Preparations</drugdosageform>
<drugadministrationroute>047</drugadministrationroute>


<drugstartdateformat>102</drugstartdateformat>
<drugstartdate>20230611</drugstartdate>
<drugenddateformat>102</drugenddateformat>
<drugenddate>20230611</drugenddate>


<actiondrug>0</actiondrug>


<activesubstance>
<activesubstancename>Levofloxacin Hydrochloride Eye Drops</activesubstancename>
</activesubstance>
<drugreactionrelatedness>


<drugassessmentsource>Reporter</drugassessmentsource>
<drugassessmentmethod>Global Introspection</drugassessmentmethod>
<drugresult>related</drugresult>
</drugreactionrelatedness><drugreactionrelatedness>


<drugassessmentsource>Company</drugassessmentsource>
<drugassessmentmethod>Global Introspection</drugassessmentmethod>
<drugresult>related</drugresult>
</drugreactionrelatedness></drug><summary>
<narrativeincludeclinical>On June 11, 2023, the patient came to our hospital for ametropia and wanted to undergo FS-LASIK refractive error correction surgery, and was given preoperative prophylactic administration of 0.488% levofloxacin hydrochloride eye drops for dropping eyes. The patient reported eye pain and conjunctival hyperemia after drug administration. The doctor diagnosed that the medication was irritating and allergic, so it was discontinued, and the symptoms disappeared after discontinuation of the medication and the surgery was performed normally.</narrativeincludeclinical>
</summary></patient></safetyreport>
</ichicsr>